Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ethionamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 5/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
| ▸ | KDM5D | Q9BY66 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethionamide SCHEMBL788546 | 1.00 | CYP1A2 (1.00) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| Ethionamide SCHEMBL12264093 | 1.00 | CYP1A2 (1.00) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| Ethionamide SCHEMBL12264095 | 1.00 | CYP1A2 (1.00) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| Ethionamide SCHEMBL27007 | 1.00 | CYP1A2 (1.00) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| Ethionamide SCHEMBL12264086 | 1.00 | CYP1A2 (1.00) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| Ethionamide SCHEMBL12264085 | 1.00 | CYP1A2 (1.00) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| Ethionamide SCHEMBL12264090 | 1.00 | CYP1A2 (1.00) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| Ethionamide SCHEMBL12264091 | 1.00 | CYP1A2 (1.00) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| Ethionamide SCHEMBL12264084 | 1.00 | CYP1A2 (1.00) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| Ethionamide SCHEMBL15869612 | 0.98 | CYP1A2 (0.96) | CYP1A2POLBKDM4ELMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113340888-B | Reagent, kit and detection method for quantitative detection of blood iodine | 长沙塞克陆德医疗科技有限公司 | 2023-11-21 | — | — | CN | claimed |
| CN-112595710-B | Rapid detection kit and detection method for iodide ions in serum sample | 长沙塞克陆德医疗科技有限公司 | 2023-05-12 | — | — | CN | claimed |
| EP-4570077-A1 | FEED PELLETS TO IMPROVE INTESTINAL HEALTH IN DOGS AND CATS | United Petfood Producers NV (BE) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025098474-A1 | TRIAZINE RING SUBSTITUTED PHENYLSULFONYL UREA COMPOUND, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE | 青岛清原化合物有限公司 | 2025-05-15 | — | — | WO | disclosed |
| EP-4549574-A2 | ANTI-TMEM-180 ANTIBODY, ANTICANCER DRUG AND CANCER TESTING METHOD | National Cancer Center Japan (JP) | 2025-05-07 | — | — | EP | disclosed |
| CN-114127265-B | Methods for enhancing stem cell efficacy by using ethionamide | 社会福祉法人三星生命公益财团 | 2025-02-14 | — | — | CN | disclosed |
| US-20250020633-A1 | Discovering Active Components in Herbals by Manipulating Common Elements | ZHANG JIANYI (US) | 2025-01-16 | — | — | US | disclosed |
| US-20240397946-A1 | CONCENTRATED FUNGICIDAL COMPOSITION OF AZOXYSTROBIN, CYPROCONAZOLE AND CHLOROTHALONIL OF HIGH LOAD, FORMULATIONS AND METHOD TO CONTROL ASIAN RUST AND OTHER DISEASES | OURO FINO QUÍMICA S/A (BR) | 2024-12-05 | — | — | US | disclosed |
| US-20240335497-A1 | PULSE PROTEIN-BASED COMPOSITION FOR ACTIVATING THE SYNTHESIS OF FGF19 | ROQUETTE FRERES (FR) | 2024-10-10 | — | — | US | disclosed |
| EP-4427590-A2 | ANTIBODY DRUG CONJUGATES AND METHODS FOR MAKING THEREOF | Novartis AG (CH) | 2024-09-11 | — | — | EP | disclosed |
| EP-3167056-B1 | CAMEL CHYMOSIN ENZYME COMPOSITION WITH IMPROVED PHYSICAL STABILITY | CHR HANSEN AS (DK) | 2024-09-11 | — | — | EP | disclosed |
| EP-4102989-A2 | EDIBLE ANIMAL CHEWS | MARS, INCORPORATED (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-110997674-B | 6-5 fused rings as C5a inhibitors | 凯莫森特里克斯股份有限公司 | 2022-12-20 | — | — | CN | disclosed |
| US-11524074-B2 | Cancer-cell-specific anti-TMEM-180 monoclonal antibody, anticancer drug, and cancer testing method | NATIONAL CANCER CENTER (JP) | 2022-12-13 | — | — | US | disclosed |
| WO-2022221720-A1 | ANTIBODY DRUG CONJUGATES AND METHODS FOR MAKING THEREOF | NOVARTIS AG (CH) | 2022-10-20 | — | — | WO | disclosed |
| CN-115066183-A | Edible animal chew | 马斯公司 | 2022-09-16 | — | — | CN | disclosed |
| EP-2547440-B1 | MULTICAPILLARY MONOLITH | PARMENTIER FRANCOIS (FR) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022166665-A1 | CHIMERIC ANTIGEN RECEPTOR WITH ENDOGENOUS PROTEIN MOLECULE REPLACING SINGLE DOMAIN ANTIBODY | 浙江大学 | 2022-08-11 | — | — | WO | disclosed |
| CN-112825859-B | Bactericidal composition and application thereof | 沈阳中化农药化工研发有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-3959326-A1 | INDUSTRIAL FERMENTATION PROCESS FOR MICROBIAL CELLS USING A FED-BATCH PRE-CULTURE | BASF SE (DE) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524074-B2 | Cancer-cell-specific anti-TMEM-180 monoclonal antibody, anticancer drug, and cancer testing method | TMEM205, TMEM120A, TMEM70 | CYP1A2 4668/4885POLB 4699/4885KDM4E 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.